menu
    • menu
    [{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strongbridge Biopharma \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Avenue Venture Opportunities Fund"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strongbridge Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strongbridge Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strongbridge Biopharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Jefferies"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ SVB Leerink"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Adage Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Adage Capital Partners"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Sanwa Kagaku Kenkyusho","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Sanwa Kagaku Kenkyusho","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Sanwa Kagaku Kenkyusho"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ SVB Leerink"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ SVB Leerink"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LeaderMed Group","sponsor":"Combiphar","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"LM-008","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"LeaderMed Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LeaderMed Group \/ Combiphar","highestDevelopmentStatusID":"10","companyTruncated":"LeaderMed Group \/ Combiphar"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Icon Plc"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"DiaUnion","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ DiaUnion","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ DiaUnion"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"JDRF","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ JDRF","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ JDRF"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"DPP-4","graph1":"Endocrinology","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Prague Scientific \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prague Scientific \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"CinRx Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ CinRx Pharma","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ CinRx Pharma"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Samsara BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Samsara BioCapital"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"G42 Investments","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ G42 Investments","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ G42 Investments"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Reneo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Reneo Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Reneo Pharmaceuticals"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Insulin Efsitora Alpha","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Insulin Efsitora Alpha","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apabetalone","moa":"||BET","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apabetalone","moa":"||BET","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apabetalone","moa":"||BET","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apabetalone","moa":"||BET","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apabetalone","moa":"BET","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Hefei Tianmai Biotechnology Development","sponsor":"Oramed Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hefei Tianmai Biotechnology Development","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hefei Tianmai Biotechnology Development \/ Oramed Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hefei Tianmai Biotechnology Development \/ Oramed Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eli Lilly \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Hefei Tianhui Biotech","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Agreement","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Hefei Tianhui Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Hefei Tianhui Biotech"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Medicox Co.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Agreement","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Medicox Co.","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Medicox Co."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"National Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Public Offering","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ National Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ National Securities Corporation"},{"orgOrder":0,"company":"Sigrid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Synthetic Amorphous Silicon Dioxide","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sigrid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Dry Powder","sponsorNew":"Sigrid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sigrid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"LYFE Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2021","type":"Series B Financing","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ LYFE Capital","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ LYFE Capital"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"HK inno.N","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ HK inno.N","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ HK inno.N"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"||Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hua Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Dorzagliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hua Medicine \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medicine \/ Bayer AG"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"||Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hua Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anji Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anji Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Population Health Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anji Pharmaceutical \/ Population Health Partners","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharmaceutical \/ Population Health Partners"},{"orgOrder":0,"company":"Metavant Sciences","sponsor":"Poxel","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imeglimin Hydrochloride","moa":"GSIS","graph1":"Endocrinology","graph2":"Phase III","graph3":"Metavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Metavant Sciences \/ Poxel","highestDevelopmentStatusID":"10","companyTruncated":"Metavant Sciences \/ Poxel"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"||GLP-1\/GCGR receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Hangzhou Jiuyuan Gene Engineering","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hangzhou Jiuyuan Gene Engineering","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hangzhou Jiuyuan Gene Engineering \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Jiuyuan Gene Engineering \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"||GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Insulin","moa":"PTK","graph1":"Endocrinology","graph2":"Phase III","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biocon \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genexine","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Eftansomatropin Alpha","moa":"IGF-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genexine \/ I-Mab Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Genexine \/ I-Mab Biopharma"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Genexine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Eftansomatropin Alpha","moa":"IGF-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"I-Mab Biopharma \/ Genexine","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ Genexine"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Eftansomatropin Alpha","moa":"IGF-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Genexine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Eftansomatropin Alpha","moa":"IGF-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"I-Mab Biopharma \/ Genexine","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ Genexine"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"I-Mab Hangzhou Company","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2024","type":"Divestment","leadProduct":"Eftansomatropin Alpha","moa":"IGF-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"I-Mab Biopharma \/ I-Mab Hangzhou Company","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ I-Mab Hangzhou Company"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Ascendis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Ascendis Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Visen Pharmaceuticals \/ Ascendis Pharma"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Avexitide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Sectoral Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Series B Financing","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Sectoral Asset Management","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Sectoral Asset Management"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Series C Financing","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Sofinnova Partners","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Sofinnova Partners"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Redalsomatropin Alpha","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Public Offering","leadProduct":"Avexitide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.059999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amylyx Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Public Offering","leadProduct":"Avexitide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.059999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amylyx Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Financing","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Endocrinology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Desmopressin Acetate","moa":"V2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            vTv Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            vTv Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            vTv Resumes Screening in Phase 3 CATT1 Trial for Liver-Targeted Cadisegliatin

                            Details : TTP399 (cadisegliatin) is a novel, oral small molecule, liver selective glucokinase activator being investigated as first-in-class oral adjunctive treatment to insulin for type 1 diabetes (T1D).

                            Product Name : TTP399

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 15, 2025

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rezolute

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Rezolute

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ersodetug

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Breakthrough Status to Rezolute's Ersodetug for Hyperinsulinism

                            Details : RZ358, which is an insulin receptor allosteric site activator. Currently, it is being evaluated for the treatment of hypoglycemia due to congenital hyperinsulinism.

                            Product Name : RZ358

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 05, 2025

                            Lead Product(s) : Ersodetug

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eton Pharmaceuticals

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Eton Pharmaceuticals

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Desmopressin Acetate

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

                            Details : ET-600, Eton’s proprietary, patented oral solution of desmopressin (V2R stimulator) under development for the treatment of central diabetes insipidus.

                            Product Name : ET-600

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            April 28, 2025

                            Lead Product(s) : Desmopressin Acetate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Camurus

                            Sweden arrow
                            IFT FIRST
                            Not Confirmed

                            Camurus

                            Sweden arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Octreotide Acetate

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CHMP Recommends Approval of Oczyesa for Treatment of Acromegaly in the EU

                            Details : Oczyesa, octreotide is a subcutaneous depot (CAM2029), for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

                            Product Name : Oczyesa

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            April 25, 2025

                            Lead Product(s) : Octreotide Acetate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eli Lilly

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orforglipron Calcium Hydrate

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lilly’s Oral GLP-1 Orforglipron Shows Success in Phase 3 with Comparable Safety

                            Details : LY3502970 (orforglipron hemicalcium hydrate) is a once-daily oral nonpeptide GLP-1 receptor agonist. It is being evaluated in phase 3 clinical trials for the treatment of adults with Type 2 Diabetes.

                            Product Name : LY3502970

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 17, 2025

                            Lead Product(s) : Orforglipron Calcium Hydrate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Crinetics Pharmaceuticals

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Crinetics Pharmaceuticals

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paltusotine

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Crinetics Pharma Gains EMA Validation for Paltusotine MAA, Orphan Drug Status

                            Details : CRN00808 (paltusotine) is an oral selective nonpeptide somatostatin receptor type 2 biased agonist, being evaluated for the treatment of patients with non-pharmacologically treated acromegaly.

                            Product Name : CRN00808

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 27, 2025

                            Lead Product(s) : Paltusotine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            vTv Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            vTv Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            vTv Therapeutics Says FDA Lifts Clinical Hold on Cadisegliatin Program for Diabetes

                            Details : TTP399 (cadisegliatin) is a novel, oral small molecule, liver selective glucokinase activator being investigated as first-in-class oral adjunctive treatment to insulin for type 1 diabetes (T1D).

                            Product Name : TTP399

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AstraZeneca

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eneboparatide Meets Primary Endpoint in CALYPSO Phase 3 for Hypoparathyroidism

                            Details : AZP-3601 (neboparatide) is a peptide agonist of the PTH1 receptor. Currently, being evaluated for the treatment of Chronic Hypoparathyroidism.

                            Product Name : AZP-3601

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Eton Pharmaceuticals

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Eton Pharmaceuticals

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Desmopressin Acetate

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eton Pharma Reports Positive Pivotal Study Results for ET-600 Candidate

                            Details : ET-600 is a proprietary, patented oral solution of desmopressin, which is under development for the treatment of central diabetes insipidus.

                            Product Name : ET-600

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            March 14, 2025

                            Lead Product(s) : Desmopressin Acetate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Corcept Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Corcept Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relacorilant

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Files Corcept's NDA for Relacorilant in Hypercortisolism Treatment

                            Details : CORT125134 (relacorilant) is a selective cortisol modulator that binds to the glucocorticoid receptor. It is being evaluated for the treatment of cushing’s syndrome.

                            Product Name : CORT125134

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 03, 2025

                            Lead Product(s) : Relacorilant

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth